These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36991229)

  • 1. Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.
    Gando Y; Yasu T
    Ann Hematol; 2023 May; 102(5):1283-1285. PubMed ID: 36991229
    [No Abstract]   [Full Text] [Related]  

  • 2. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 3. Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
    Xia L; Tian W; Zhao Y; Jiang L; Qian W; Jiang L; Ge L; Li J; Jin F; Yang M
    Signal Transduct Target Ther; 2023 May; 8(1):176. PubMed ID: 37130896
    [No Abstract]   [Full Text] [Related]  

  • 4. Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.
    Kobayashi T; Sato H; Miura M; Fukushi Y; Kuroki W; Ito F; Teshima K; Watanabe A; Fujishima N; Kobayashi I; Kameoka Y; Takahashi N
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):285-296. PubMed ID: 38782790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
    [No Abstract]   [Full Text] [Related]  

  • 6. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 7. High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
    Matsuda K; Yoshida T; Sugimoto K
    Ann Hematol; 2023 Apr; 102(4):971-972. PubMed ID: 36820906
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
    Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
    [No Abstract]   [Full Text] [Related]  

  • 10. Ex vivo drug sensitivity profiling-guided treatment of a relapsed pediatric mixed-phenotype acute leukemia with venetoclax and azacitidine.
    Gonzales F; Guilmatre A; Barthélémy A; Lapillonne H; Pottier N; Leverger G; Petit A; Cheok MH
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29678. PubMed ID: 35353439
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis.
    Edahiro T; Ureshino H; Chishaki R; Fujino K; Mino T; Yoshida T; Fukushima N; Ichinohe T
    Leuk Lymphoma; 2022 Dec; 63(14):3511-3512. PubMed ID: 36098247
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
    Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
    [No Abstract]   [Full Text] [Related]  

  • 13. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
    Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
    Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
    [No Abstract]   [Full Text] [Related]  

  • 14. Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
    Lucijanic M; Tomasovic-Loncaric C; Stoos-Veic T; De Both T; Jalsenjak B; Kusec R
    Ann Hematol; 2024 Feb; 103(2):671-672. PubMed ID: 37946030
    [No Abstract]   [Full Text] [Related]  

  • 15. Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia.
    Ramdohr F; Hennings R; Monecke A; Kayser S
    Haematologica; 2023 Jul; 108(7):1965-1967. PubMed ID: 36546450
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
    Niswander LM; Chung P; Diorio C; Tasian SK
    Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.
    Jonas BA; DiNardo C; Fracchiolla N; Pristupa A; Ishizawa K; Jin J; Konopleva M; Ofran Y; Montesinos P; Kovacsovics T; Jang JH; Kantarjian H; Duan Y; Potluri J; Werner M; Pratz KW
    Am J Hematol; 2022 Nov; 97(11):E422-E425. PubMed ID: 36053878
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].
    Liu XH; Wu Y; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):166. PubMed ID: 35381683
    [No Abstract]   [Full Text] [Related]  

  • 20. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
    Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.